{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:43:47Z","timestamp":1790419427529,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.bone.2010.12.024","type":"journal-article","created":{"date-parts":[[2011,1,12]],"date-time":"2011-01-12T10:43:48Z","timestamp":1294829028000},"page":"77-81","source":"Crossref","is-referenced-by-count":134,"title":["The kidney and bisphosphonates"],"prefix":"10.1016","volume":"49","author":[{"given":"Paul D.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2010.12.024_bb0005","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2010.12.024_bb0010","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0889-8529(05)70014-1","article-title":"Treatment of osteoporosis with bisphosphonates","volume":"27","author":"Watts","year":"1998","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.bone.2010.12.024_bb0020","first-page":"1","article-title":"Chronic kidney disease and bone fracture: a growing concern","volume":"2","author":"Nickolas","year":"2008","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.bone.2010.12.024_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","article-title":"Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Examination Survey","volume":"41","author":"Coresh","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.bone.2010.12.024_bb0030","series-title":"Bisphosphonate therapy in acute and chronic bone loss","first-page":"231","article-title":"Pharmacodynamics of bisphosphonates in man: implications for treatment","author":"Papapoulos","year":"1995"},{"key":"10.1016\/j.bone.2010.12.024_bb0035","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","article-title":"Bisphosphonates: from the laboratory to the clinic and back again","volume":"25","author":"Russell","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.12.024_bb0040","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1023\/A:1011024200280","article-title":"Risedronate pharmacokinetics and intra- and inter-subject variability upon single dose intravenous and oral administration","volume":"18","author":"Mitchell","year":"2001","journal-title":"Pharm Res"},{"key":"10.1016\/j.bone.2010.12.024_bb0045","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1997.12.10.1700","article-title":"Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis","volume":"12","author":"Kahn","year":"1997","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.12.024_bb0050","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.tiv.2008.01.006","article-title":"Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety","volume":"22","author":"Luhe","year":"2008","journal-title":"Toxicol In Vitro"},{"key":"10.1016\/j.bone.2010.12.024_bb0055","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/ki.1975.70","article-title":"Renal secretion of diphosphonates in rats","volume":"8","author":"Troehler","year":"1975","journal-title":"Kidney Int"},{"key":"10.1016\/j.bone.2010.12.024_bb0060","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/ncpneph0076","article-title":"Drug-associated renal dysfunction and injury","volume":"2","author":"Choudhury","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.bone.2010.12.024_bb0065","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","article-title":"Pharmacokinetics and pharmacodynamics of zolendronic acid in cancer patients with bone metastases","volume":"42","author":"Chen","year":"2002","journal-title":"J Clin Pharmacol"},{"issue":"suppl 17","key":"10.1016\/j.bone.2010.12.024_bb0070","first-page":"38","article-title":"Comparison of risedronate and alendronate pharmacokinetics at clinical doses","author":"Phipps","year":"2003","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.bone.2010.12.024_bb0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00044011-200525020-00003","article-title":"Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates","volume":"25","author":"Lasseter","year":"2005","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.bone.2010.12.024_bb0080","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/00912700022008928","article-title":"Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers","volume":"40","author":"Mitchell","year":"2000","journal-title":"J Clin Pharmacol"},{"issue":"suppl 1","key":"10.1016\/j.bone.2010.12.024_bb0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.10-90001-3","article-title":"Preclinical perspectives on bisphosphonate renal safety","volume":"19","author":"Body","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.bone.2010.12.024_bb0090","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0169-6009(91)90131-I","article-title":"Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia","volume":"15","author":"Dumon","year":"1991","journal-title":"Bone Miner"},{"key":"10.1016\/j.bone.2010.12.024_bb0095","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3109\/08860229409044906","article-title":"Acute renal failure associated with the administration of parenteral etidronate","volume":"16","author":"O'Sullivan","year":"1994","journal-title":"Ren Fail"},{"key":"10.1016\/j.bone.2010.12.024_bb0100","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0140-6736(83)92434-0","article-title":"Effects of intravenous diphosphonates on renal function","volume":"1","author":"Kanis","year":"1983","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bone.2010.12.024_bb0105","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2165\/00002018-199614030-00003","article-title":"Adverse effects of bisphosphonates: a comparative review","volume":"14","author":"Adami","year":"1996","journal-title":"Drug Saf"},{"key":"10.1016\/j.bone.2010.12.024_bb0110","series-title":"Aredia (pamidronate) [injection prescribing information]","year":"2007"},{"key":"10.1016\/j.bone.2010.12.024_bb0115","series-title":"Zometa (zoledronic acid) [injection prescribing information]","year":"2007"},{"key":"10.1016\/j.bone.2010.12.024_bb0120","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","article-title":"Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate","volume":"12","author":"Markowitz","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.bone.2010.12.024_bb0125","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.bone.2010.12.024_bb0130","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0272-2712(18)30474-8","article-title":"Assessment of renal function in the old. Special considerations","volume":"13","author":"Lindeman","year":"1993","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.bone.2010.12.024_bb0135","series-title":"Diseases of the kidney","first-page":"333","article-title":"Laboratory evaluation of renal function","author":"Lafayette","year":"1993"},{"key":"10.1016\/j.bone.2010.12.024_bb0140","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1097\/01.ASN.0000088721.98173.4B","article-title":"A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease","volume":"14","author":"Lin","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.bone.2010.12.024_bb0145","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1359\/JBMR.050817","article-title":"Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.bone.2010.12.024_bb0150","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1359\/jbmr.070112","article-title":"Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial","volume":"22","author":"Jamal","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.12.024_bb0155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bone.2010.12.024_bb0160","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.bone.2010.12.024_bb0165","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2215\/CJN.02870608","article-title":"Reporting eGFR","volume":"3","author":"Bennett","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.bone.2010.12.024_bb0170","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.2215\/CJN.00960208","article-title":"Screening for CKD with eGFR: doubts and dangers","volume":"3","author":"Glassock","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.bone.2010.12.024_bb0175","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.12.024_bb0180","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.12.024_bb0185","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study","volume":"54","author":"Delmas","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bone.2010.12.024_bb0190","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.bone.2010.12.024_bb0195","first-page":"S1","article-title":"National Kidney Foundation K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.bone.2010.12.024_bb0200","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.V74556","article-title":"Effects of diet and antihypertensive therapy on creatinine clearance and serum creatinine concentration in the Modification of Diet in Renal Disease Study","volume":"7","author":"Levey","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.bone.2010.12.024_bb0210","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/ki.2008.193","article-title":"Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women","volume":"74","author":"Boonen","year":"2008","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.bone.2010.12.024_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14740338.6.6.663","article-title":"Renal safety of intravenous bisphosphonates in the treatment of osteoporosis","volume":"6","author":"Lewiecki","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.bone.2010.12.024_bb0220","volume":"Volume 2","author":"US Food and Drug Administration (FDA)","year":"2009"},{"issue":"3","key":"10.1016\/j.bone.2010.12.024_bb0225","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s00198-004-1690-6","article-title":"A new significant and independent risk factor for falls in elderly men and women: a low creatinine clearance of less than 65ml\/min","volume":"16","author":"Dukas","year":"2005","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.bone.2010.12.024_bb0230","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1001\/archinte.167.2.133","article-title":"Renal function and risk of hip and vertebral fractures in older women","volume":"167","author":"Ensrud","year":"2007","journal-title":"Arch Intern Med"},{"issue":"11","key":"10.1016\/j.bone.2010.12.024_bb0235","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1681\/ASN.2005111194","article-title":"Relationship between moderate to severe kidney disease and hip fracture in the United States","volume":"17","author":"Nickolas","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"113","key":"10.1016\/j.bone.2010.12.024_bb0240","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","year":"2009","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"10.1016\/j.bone.2010.12.024_bb0245","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11914-005-0021-y","article-title":"Treatment of osteoporosis in chronic kidney disease and end-stage renal disease","volume":"3","author":"Miller","year":"2005","journal-title":"Curr Osteoporos Rep"},{"issue":"5","key":"10.1016\/j.bone.2010.12.024_bb0250","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1525-139X.2007.00319.x","article-title":"Osteoporosis and chronic kidney disease","volume":"20","author":"Gal-Moscovici","year":"2007","journal-title":"Semin Dial"},{"issue":"2","key":"10.1016\/j.bone.2010.12.024_bb0255","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.semnephrol.2009.01.007","article-title":"Diagnosis and treatment of osteoporosis in chronic renal disease","volume":"29","author":"Miller","year":"2009","journal-title":"Semin Nephrol"},{"issue":"12","key":"10.1016\/j.bone.2010.12.024_bb0260","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3949\/ccjm.76a.08108","article-title":"Fragility fractures in chronic kidney disease: an opinion-based approach","volume":"76","author":"Miller","year":"2009","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.bone.2010.12.024_bb0265","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ki.2010.113","article-title":"Use of vitamin D in chronic kidney disease patients","volume":"78","author":"Gal-Moscovici","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.bone.2010.12.024_bb0270","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","article-title":"The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women","volume":"18","author":"Kanis","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2010.12.024_bb0275","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-009-1034-7","article-title":"The potential impact of the new National Osteoporosis Foundation guidance on treatment patterns","volume":"21","author":"Dawson-Hughes","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2010.12.024_bb0280","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.12.024_bb0285","unstructured":"Jamal1 SA, Ljunggren2 O, Stehman-Breen3 C, Cummings4 SR, McClung5 MR, Goemaere6 S, Ebeling7 PR, Franek8 E, Yang3 Y, Egbuna3 OI, Steven Boonen9, Miller10 PD. The effects of denosumab on fracture and bone mineral density (BMD) by level of renal function. J Bone Miner Res in press."},{"key":"10.1016\/j.bone.2010.12.024_bb0290","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","article-title":"Teriparatide in postmenopausal women with osteoporosis and impaired renal function","volume":"18","author":"Miller","year":"2007","journal-title":"Osteoporos Int"},{"issue":"11","key":"10.1016\/j.bone.2010.12.024_bb0295","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.bone.2010.12.024_bb0300","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/j.ajkd.2007.08.019","article-title":"Increased risk of hip fracture among men with CKD","volume":"51","author":"Dooley","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.bone.2010.12.024_bb0305","first-page":"115","article-title":"Osteoporosis in end-state renal disease","volume":"19","author":"Lindberg","year":"1999","journal-title":"Semin Nephrol"},{"issue":"Suppl 3","key":"10.1016\/j.bone.2010.12.024_bb0310","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2215\/CJN.02430508","article-title":"The role of bone biopsy in patients with chronic renal failure","volume":"3","author":"Miller","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.bone.2010.12.024_bb0315","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1525-139X.2007.00271.x","article-title":"Is there a role for bisphosphonates in chronic kidney disease?","volume":"20","author":"Miller","year":"2007","journal-title":"Semin Dial"},{"issue":"2","key":"10.1016\/j.bone.2010.12.024_bb0320","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.semnephrol.2009.01.008","article-title":"The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature","volume":"29","author":"Hruska","year":"2009","journal-title":"Semin Nephrol"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328210021381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328210021381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T05:58:50Z","timestamp":1637128730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328210021381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S8756328210021381"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2010.12.024","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}